Despite their promise, ADCs face several challenges:
- Heterogeneity of Antigen Expression: Not all cancer cells express the target antigen uniformly, which can lead to incomplete tumor eradication. - Development of Resistance: Cancer cells can develop resistance to the cytotoxic drug or alter antigen expression over time. - Toxicity: Although ADCs are designed to be more selective, off-target effects and toxicity can still occur, particularly if the target antigen is also present on normal cells.
